Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis.

Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J.

Ann Hepatol. 2013 May-Jun;12(3):364-72. Review.

2.

Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y.

Clin Exp Med. 2012 Sep;12(3):159-64. doi: 10.1007/s10238-011-0160-7.

PMID:
22002708
3.

Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.

Lai J, Yan Y, Mai L, Zheng YB, Gan WQ, Ke WM.

Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):154-9.

4.

[Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].

Fan LY, Zhou Z, Zhong S, Ling N, Wang ZY, Shi XF, Zhang DZ, Ren H.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jun;17(6):429-33. Chinese.

PMID:
19567021
5.

Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.

Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1004-10.e1. doi: 10.1016/j.cgh.2013.01.026.

PMID:
23376799
6.

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL.

Gastroenterology. 2010 Aug;139(2):491-8. doi: 10.1053/j.gastro.2010.03.059.

PMID:
20381492
7.

Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.

Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG.

World J Gastroenterol. 2015 Jan 14;21(2):584-92. doi: 10.3748/wjg.v21.i2.584.

8.

Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C.

Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014.

PMID:
22796241
9.

What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM.

World J Gastroenterol. 2012 Sep 7;18(33):4604-9. doi: 10.3748/wjg.v18.i33.4604.

10.

Treatment of chronic hepatitis B virus infection - Dutch national guidelines.

Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and Hepatologists..

Neth J Med. 2008 Jul-Aug;66(7):292-306. Review.

11.

Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?

Papatheodoridis GV.

Liver Int. 2013 Feb;33 Suppl 1:151-6. doi: 10.1111/liv.12054. Review.

PMID:
23286859
12.

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.

Gastroenterology. 2012 Sep;143(3):619-28.e1. doi: 10.1053/j.gastro.2012.05.037.

PMID:
22643350
13.

[The impact of early rapid virological response on the outcomes of hepatitis B associated acute on chronic liver failure during antiviral treatment].

Chen L, Zheng CX, Lin MH, Gan QR, Lin RS, Gao HB, Huang JR, Pan C.

Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):734-7. doi: 10.3760/cma.j.issn.1007-3418.2011.10.004. Chinese.

PMID:
22409843
14.
15.

Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.

Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.

J Viral Hepat. 2013 Jul;20(7):502-9. doi: 10.1111/jvh.12054.

PMID:
23730844
16.

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.

Sun LJ, Yu JW, Zhao YH, Kang P, Li SC.

J Gastroenterol Hepatol. 2010 Mar;25(3):583-90. doi: 10.1111/j.1440-1746.2009.06089.x.

PMID:
19968744
17.

[Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load].

Chen LB, Cao H, Zhang YF, Shu X, Chen N, Zhang K, Li G, Xu QH.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010 Oct;24(5):364-6. Chinese.

PMID:
21280326
18.

Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.

Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS Jr.

Transplantation. 2013 Apr 15;95(7):960-5. doi: 10.1097/TP.0b013e3182845f97.

PMID:
23545507
19.

Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.

Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.

J Gastroenterol Hepatol. 2012 Oct;27(10):1589-95. doi: 10.1111/j.1440-1746.2012.07167.x.

PMID:
22554121
20.

Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.

Leemans WF, Ter Borg MJ, de Man RA.

Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:171-82. doi: 10.1111/j.1365-2036.2007.03481.x. Review.

Supplemental Content

Support Center